Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Early Access Program With Inolimomab in Steroid-refractory Acute Graft Versus Host Disease Grade II-IV in Adults and in Children Over 28 Days of Age

Next Previous
X
Search
Trial Profile

Early Access Program With Inolimomab in Steroid-refractory Acute Graft Versus Host Disease Grade II-IV in Adults and in Children Over 28 Days of Age

Status: Recruiting
Phase of Trial: Clinical Phase Unknown

Latest Information Update: 22 Jul 2022

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Inolimomab (Primary)
  • Indications Graft-versus-host disease
  • Focus Adverse reactions; Expanded access; Therapeutic Use
  • Sponsors ElsaLys Biotech

    • Most Recent Events

    • 19 Apr 2021 New trial record
    • 15 Apr 2021 According to an ElsaLys Biotech media release, the company expects to collect clinical benefit and safety profile data through these compassionate use programs, which will support the companys work on the filing of marketing authorization applications (MAA) in Europe and in the U.S.
    • 15 Apr 2021 According to an ElsaLys Biotech media release, the number of patients included in the cohort ATU in France since December 2019 reflects a real medical need. This is the reason why ElsaLys is working on expanding compassionate use programs for inolimomab in a number of European countries. Several early access applications will be submitted. The indication should be discussed during a multidisciplinary consultation meeting.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top